Ticagrelor Tablet, Film Coated
Product Images NDC 70756-048

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 70756-048). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lifestar Pharma Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure3 (D2d806f1 5c7d 4af8 9e0b 76af0e2d482a 01)

A Kaplan-Meier cumulative percentage graph comparing Ticagrelor and placebo over 54 months from randomization. The graph shows cumulative event percentages for Ticagrelor (solid line) and placebo (dashed line), with participant counts at risk below the x-axis for multiple time points.*

FDA Label Image

Figure4 (D2d806f1 5c7d 4af8 9e0b 76af0e2d482a 02)

A cumulative percentage chart comparing events over days from randomization for Ticagrelor 90 mg twice daily versus placebo. The plot shows time on the x-axis (up to 34 days) and cumulative percentage on the y-axis (up to 1.0%). Ticagrelor data is shown as a solid line, placebo as a dashed line. The chart includes a risk table indicating the number of subjects at risk for each group across time points.*

FDA Label Image

Chemical Structure (D2d806f1 5c7d 4af8 9e0b 76af0e2d482a 03)

Chemical structure of Ticagrelor showing its molecular framework with functional groups including a cyclopropyl ring, fluorinated phenyl ring, and hydroxyl groups attached to a complex bicyclic structure.*

FDA Label Image

Figure_5 (D2d806f1 5c7d 4af8 9e0b 76af0e2d482a 04)

A line graph showing the percentage of IPA induced by 20uM ADP over time (hours) for three treatments: Ticagrelor 180 mg, Clopidogrel 600 mg, and Placebo. Ticagrelor shows a rapid increase to about 90% by 2 hours, maintained through 8 hours. Clopidogrel rises more gradually to about 50%, and Placebo shows minimal change over the same period.*

FDA Label Image

Figure_6 (D2d806f1 5c7d 4af8 9e0b 76af0e2d482a 05)

A line graph comparing IPA (%) induced by 20µM ADP over time (days) for Ticagrelor, Clopidogrel, and Placebo. Ticagrelor shows a rapid initial increase followed by a decline. Clopidogrel shows a slower increase with a smaller peak, and placebo remains low and stable. An inset graph displays the same IPA (%) over 48 hours, emphasizing early time points.*

FDA Label Image

Figure7 (D2d806f1 5c7d 4af8 9e0b 76af0e2d482a 06)

A forest plot illustrating the mean effect and 90% confidence interval for various intrinsic factors such as age, gender, ethnicity, renal impairment, end stage renal disease, and mild hepatic impairment on the pharmacokinetics of Ticagrelor compared to a reference drug, AR-C124910XX. The chart indicates recommendations regarding dose adjustment as 'No dose adjustment' for all factors.*

FDA Label Image

Figure_8 (D2d806f1 5c7d 4af8 9e0b 76af0e2d482a 07)

A chart titled 'Mean effect and 90% CI' showing the interaction effects of various drugs with Ticagrelor (AR-C124910XX). The chart has two columns of markers indicating pharmacokinetic parameters Cmax and AUC for each interacting drug, along with recommendations beside each. It includes drugs like ketoconazole, diltiazem, rifampin, aspirin, desmopressin, heparin, enoxaparin, cyclosporine, morphine, and fentanyl, with recommendations ranging from 'avoid concomitant use' to 'no dose adjustment' or references to specific sections for further details.*

FDA Label Image

Figure9 (D2d806f1 5c7d 4af8 9e0b 76af0e2d482a 08)

A chart displaying the mean effects and 90% confidence intervals of various interacting drugs with ticagrelor dose. The chart compares change relative to interacting drug alone on a horizontal axis, plotting Cmax and AUC values for drugs including simvastatin, atorvastatin, levonorgestrel, ethinyl estradiol, tolbutamide, digoxin, and cyclosporine. Recommendations for dose adjustments are shown on the right, with most drugs indicating no dose adjustment except simvastatin which recommends a maximum dose of 40 mg.*

FDA Label Image

Figure15 (D2d806f1 5c7d 4af8 9e0b 76af0e2d482a 09)

A cumulative percentage line graph comparing Ticagrelor and placebo over months from randomization. The x-axis shows time in months (0 to 54), and the y-axis shows cumulative percentage. Two lines represent events in Ticagrelor and placebo groups, with placebo generally higher. A table of numbers at risk is displayed below the x-axis.*

FDA Label Image

Figure_16 (D2d806f1 5c7d 4af8 9e0b 76af0e2d482a 10)

A forest plot comparing hazard ratios (HR) with 95% confidence intervals for Ticagrelor versus placebo across various patient subgroups and characteristics from a clinical dataset. The plot includes age, sex, race, body mass index, geographic region, aspirin dose, heart rate, kidney function, insulin use, medical history, time since procedures, smoking status, and diabetes duration, illustrating relative effectiveness or risk associated with Ticagrelor.*

FDA Label Image

Figure17 (D2d806f1 5c7d 4af8 9e0b 76af0e2d482a 11)

A Kaplan-Meier cumulative percentage curve chart comparing ticagrelor 90 mg twice daily versus placebo over approximately 33 days post-randomization. The y-axis shows cumulative percentage events, while the x-axis shows days from randomization. Event counts and percentages are indicated for both groups in the chart legend, with ticagrelor events lower than placebo over time.*

FDA Label Image

Figure18 (D2d806f1 5c7d 4af8 9e0b 76af0e2d482a 12)

A forest plot chart comparing the hazard ratios (HR) and 95% confidence intervals (CI) for various patient characteristics between Ticagrelor and placebo groups. The plot shows HR values across subgroups including age, sex, race, weight, BMI, geographic region, diagnosis, time intervals, diabetes, hypertension, prior ischemic events, statin treatment, and smoking status, illustrating the relative risk and confidence intervals for Ticagrelor versus placebo.*

FDA Label Image

60mgbottle (D2d806f1 5c7d 4af8 9e0b 76af0e2d482a 13)

Label for Ticagrelor Tablets 60 mg film-coated oral tablets, packaged in a 60-count container. The label shows the NDC 70756-047-60 and notes the drug is manufactured for Lifestar Pharma LLC, made in India. It includes storage instructions, a pharmacist medication guide reminder, barcodes, and QR codes for the medication guide.*

FDA Label Image

90mgbottle (D2d806f1 5c7d 4af8 9e0b 76af0e2d482a 14)

Label for Ticagrelor Tablets 90 mg film-coated oral tablets by Lifestar Pharma LLC. The label indicates a package of 60 tablets, includes storage instructions, pharmacist dispensing guidance, barcode, QR code for medication guide, and manufacturing details stating "Made in India."*

FDA Label Image

Blister Carton (D2d806f1 5c7d 4af8 9e0b 76af0e2d482a 15)

Ticagrelor Tablets 90 mg film-coated oral tablets packaging label by Lifestar Pharma LLC. The label indicates 100 unit-dose tablets (10 x 10), with warnings and storage conditions. The packaging notes that the medication guide must be dispensed to the patient separately. Made in India, with NDC 70756-048-99 displayed.*

FDA Label Image

Blister Foil (D2d806f1 5c7d 4af8 9e0b 76af0e2d482a 16)

Carton label for Ticagrelor 90 mg film-coated tablets by Lifestar Pharma LLC. The label indicates prescription-only status and includes a barcode, lot and expiration date placeholders, manufacturing information indicating product is made in India, and regulatory codes. The layout is repeated eight times on the sheet with measurement markings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.